Why Zale, Chelsea Therapeutics, and Nabors Industries Are Today's 3 Best Stocks

The S&P 500 finally succumbs to weak housing data while Zale, Chelsea Therapeutics and Nabors Industries all soar by double-digits.

Feb 19, 2014 at 5:15PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Today marked the second straight day of abysmal housing data, expect this time, the broad-based S&P 500 (SNPINDEX:^GSPC) could not escape its clutches.

Pushing generally positive earnings announcements and further merger and acquisition activity to the side, investors chose to focus on the January release of housing start data, as well as the weekly release of the Mortgage Brokers Association's Mortgage Index.

Housing starts for January were awful -- there's no way of sugarcoating it. Housing starts for January came in at an annualized rate of 888,000, a 16% plummet from January. This marks the biggest month-on-month decline in three years, and handily missed the consensus estimate of 950,000 by economists. This figure builds on yesterday's weak homebuilder sentiment, and points to growing caution that the Fed's QE3 tapering may lead to a rise in lending rates, and a halt of growth in the homebuilding sector.

In similar fashion, the MBA Mortgage Index, which measures loan originations (whether it be refinancing or new mortgage loans), fell 4.1% from last week. The index also fell 2% in the prior week. What we're seeing here is a very spoiled U.S. consumer who's become accustomed to falling rates. Even though rates are still historically low, these consumers are balking at lending rates that are roughly 100 basis points off last year's lows, which could represent bad news for the sector as a whole.

If there was a bright side to today's data, it was the 0.2% rise in the Purchasers Price Index for January. Rapid cost inflation for businesses is never a good thing, but a modest increase of 0.2%, as we're seeing here, demonstrates healthy expansion, as long as businesses can pass those price hikes successfully onto the consumer.

By day's end, the S&P 500 had finished decisively lower by 12.01 points (-0.65%), to close at 1,828.75, just the second time in the past seven sessions that it's ended lower.

Sparkling like a diamond in the rough today amid the red ink was fine jewelry chain Zale (UNKNOWN:ZLC.DL), which skyrocketed 40.3% after agreeing to be purchased for $690 million, or $21 per share, in cash by rival Signet Jewelers (NYSE:SIG), which operators Kay Jewelers. The deal will combine the nation's two largest mid-tier jewelry stores, reduce Signet's reliance on its oversea's chains by giving it a stronger presence in the U.S., contribute to about $100 million in cost synergies, and provide better buying leverage when dealing with diamond vendors. The move does make some degree of sense given that online competition is making life difficult for bricks-and-mortar retail chains, but I personally believe that Zale shareholders are getting one heck of a deal here, given how precarious its long-term debt situation remains. I remain skeptical as to whether or not Signet will benefit from this purchase anytime soon.

Also vaulting significantly higher on the day was small-cap biopharmaceutical company Chelsea Therapeutics (NASDAQ:CHTP), which advanced 24.4% after receiving approval for Northera from the Food and Drug Administration for the treatment of low blood pressure and dizziness in Parkinson's disease patients. The FDA panel's overwhelming recommendation for approval, and today's FDA approval, are still a bit of a shock because the drug seems to be quite effective over the short term (a few weeks), but it hasn't demonstrated the type of long-term effectiveness that I would have expected to see with an FDA approval. Peak sales estimates of the drug are approximately $400 million, so there's certainly room for Chelsea to run higher. The question will be whether or not it can effectively launch its new product.

Finally, land drilling oil and gas contractor Nabors Industries (NYSE:NBR) tracked higher by 13.3% after reporting strong fourth-quarter earnings results after the bell last night. For the quarter, with the assistance of tax benefits and the full recovery of receivables from a customers' bankruptcy settlement, Nabors earned an adjusted $0.42 in EPS on $1.61 billion in revenue. By comparison, Wall Street expected only $0.20 in EPS on $1.55 billion in revenue. Even backing out those one-time gains Nabors topped the Street by $0.01 per share. What really has investors excited was management's commentary that they believe this represent the low point for Nabors during an extended period of contraction. On the heels of this news, Nabors also received an upgrade to 'outperform' from 'underperform' at research firm CLSA.

Zale, Chelsea Therapeutics, and Nabors Industries may be off to the races today, but they'll likely be hard-pressed to keep up with this top stock in 2014.
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers